13G Filing: Nexthera Capital and Catalyst Biosciences Inc. (CBIO)

Page 1 of 9

Catalyst Biosciences Inc. (NASDAQ:CBIO): Ori Hershkovitz’s Nexthera Capital filed an amended 13D.

You can check out Nexthera Capital’s latest holdings and filings here.

Please follow Nexthera Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Nexthera Capital or update its stock holdings.

Follow Ori Hershkovitz's Nexthera Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Nexthera Capital 0 311,175 0 311,175 311,175 5.4%
Nexthera Capital GP 0 311,175 0 311,175 311,175 5.4%
Daniel Malek 0 311,175 0 311,175 311,175 5.4%
Ori Hershkovitz 0 311,175 0 311,175 311,175 5.4%

Follow Ori Hershkovitz's Nexthera Capital

Page 1 of 9 – SEC Filing


SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
SCHEDULE 13G
(RULE 13D – 102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)
(Amendment No.  )*
Catalyst Biosciences, Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
14888D208
(CUSIP Number)
December 20, 2017
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Gyre Therapeutics Inc. (NASDAQ:GYRE)

Page 1 of 9